Sukumar Nagendran is a highly accomplished professional with extensive experience in the biotech and healthcare sectors. Currently serving as President at Taysha Gene Therapies since August 2020, Sukumar also holds multiple leadership roles on various boards, including as a member of the Audit and Compensation Committees. Additional board memberships include Saliogen, Medocity, Neurogene, Solid Biosciences, and RTW Investments SPAC, along with a position at Project Healthy Minds, a nonprofit focused on mental health. With a strong educational background in medicine and business, including training at the Mayo Clinic and degrees from Rutgers University and The Wharton School, Sukumar is recognized for expertise in gene therapy, clinical development, and medical affairs. Previously, Sukumar served as President of R&D and Chief Medical Officer at Jaguar Gene Therapy until February 2023 and has advised several organizations, including Chardan and Encoded Therapeutics.